- Home
- BRDG vs CELC Comparison
BRDG vs CELC Comparison
Compare BRDG & CELC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BRDG
- CELC
- Stock Information
- Founded
- BRDG 2009
- CELC 2011
- Country
- BRDG United States
- CELC United States
- Employees
- BRDG N/A
- CELC N/A
- Industry
- BRDG Investment Managers
- CELC Medical Specialities
- Sector
- BRDG Finance
- CELC Health Care
- Exchange
- BRDG Nasdaq
- CELC Nasdaq
- Market Cap
- BRDG 391.6M
- CELC 399.1M
- IPO Year
- BRDG 2021
- CELC 2017
- Fundamental
- Price
- BRDG $9.33
- CELC $12.40
- Analyst Decision
- BRDG Hold
- CELC Strong Buy
- Analyst Count
- BRDG 5
- CELC 5
- Target Price
- BRDG $11.30
- CELC $30.80
- AVG Volume (30 Days)
- BRDG 315.3K
- CELC 145.0K
- Earning Date
- BRDG 06-10-2025
- CELC 05-14-2025
- Dividend Yield
- BRDG 4.98%
- CELC N/A
- EPS Growth
- BRDG N/A
- CELC N/A
- EPS
- BRDG N/A
- CELC N/A
- Revenue
- BRDG $453,729,000.00
- CELC N/A
- Revenue This Year
- BRDG N/A
- CELC N/A
- Revenue Next Year
- BRDG $36.21
- CELC N/A
- P/E Ratio
- BRDG N/A
- CELC N/A
- Revenue Growth
- BRDG 39.05
- CELC N/A
- 52 Week Low
- BRDG $6.81
- CELC $7.58
- 52 Week High
- BRDG $11.69
- CELC $19.77
- Technical
- Relative Strength Index (RSI)
- BRDG 52.51
- CELC 68.76
- Support Level
- BRDG $9.09
- CELC $11.57
- Resistance Level
- BRDG $9.37
- CELC $12.34
- Average True Range (ATR)
- BRDG 0.22
- CELC 0.53
- MACD
- BRDG -0.04
- CELC 0.16
- Stochastic Oscillator
- BRDG 45.61
- CELC 98.08
About BRDG Bridge Investment Group Holdings Inc.
Bridge Investment Group Holdings Inc is a vertically integrated investment manager, diversified across specialized asset classes. The company combines its operating platform with dedicated teams of investment professionals focused on various specialized and synergistic investment platforms, including real estate, credit, renewable energy, and secondaries strategies. Its products and vertically integrated structure allow it to capture new market opportunities and serve investors with various investment objectives. The Company operates as one business, a fully integrated real estate investment manager.
About CELC Celcuity Inc.
Celcuity Inc is a clinical-stage biotechnology company pursuing development for oncology. The Company's lead therapeutic candidate is gedatolisib, a potent pan-PI3K and mTOR inhibitor. Its mechanism of action and pharmacokinetic properties are differentiated from other currently approved and investigational therapies that target PI3K or mTOR alone or together. A Phase 3 clinical trial, VIKTORIA-1, evaluating gedatolisib in combination with fulvestrant with or without palbociclib in patients with HR+/HER2- advanced breast cancer is currently enrolling patients.